(19)
(11) EP 4 211 125 A1

(12)

(43) Date of publication:
19.07.2023 Bulletin 2023/29

(21) Application number: 20953389.2

(22) Date of filing: 10.09.2020
(51) International Patent Classification (IPC): 
C07D 317/18(2006.01)
A61K 31/357(2006.01)
C07D 317/72(2006.01)
A61P 25/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/357; A61P 25/00; A61K 31/443; A61K 31/506; A61K 31/381; A61K 31/427
(86) International application number:
PCT/KR2020/012237
(87) International publication number:
WO 2022/054987 (17.03.2022 Gazette 2022/11)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(71) Applicant: Bio-Pharm Solutions Co., Ltd.
Suwon-si, Gyeonggi-do 16229 (KR)

(72) Inventor:
  • CHOI, Yong Moon
    Irvine, California 92620 (US)

(74) Representative: Pfenning, Meinig & Partner mbB 
Patent- und Rechtsanwälte Theresienhöhe 11a
80339 München
80339 München (DE)

   


(54) SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER